AbCellera Biologics Inc. Equity Securities without Readily Determinable Fair Value, Amount
AbCellera Biologics Inc. (ABCL) had Equity Securities without Readily Determinable Fair Value, Amount of $26.40 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount · last filed 2026-08-05
- 2026-06-30: Equity Securities without Readily Determinable Fair Value, Amount $26.40M.
- 2026-03-31: Equity Securities without Readily Determinable Fair Value, Amount $32.50M.
- 2025-12-31: Equity Securities without Readily Determinable Fair Value, Amount $32.50M.
- 2025-09-30: Equity Securities without Readily Determinable Fair Value, Amount $29.10M.
| Period end | Equity Securities without Readily Determinable Fair Value, Amount |
|---|---|
| 2026-06-30 | $26.40M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $32.50M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $32.50M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $29.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $33.10M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $32.30M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $32.30M 10-K · filed 2026-02-24 |
| 2024-09-30 | $32.30M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $32.30M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $32.30M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $32.30M 10-K · filed 2025-02-27 |
| 2023-09-30 | $32.30M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $32.30M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $29.70M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $18.50M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |